Research Analysts Offer Predictions for RNAZ Q1 Earnings

TransCode Therapeutics, Inc. (NASDAQ:RNAZ) – Stock analysts at HC Wainwright lowered their Q1 2025 earnings per share (EPS) estimates for TransCode Therapeutics in a report issued on Wednesday, April 16th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings of ($2.00) per share for the quarter, down from their prior estimate of ($1.48). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for TransCode Therapeutics’ current full-year earnings is ($4.76) per share. HC Wainwright also issued estimates for TransCode Therapeutics’ Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.63) EPS, FY2026 earnings at ($0.32) EPS, FY2027 earnings at ($0.24) EPS and FY2028 earnings at ($0.20) EPS.

TransCode Therapeutics Stock Performance

RNAZ opened at $0.27 on Friday. TransCode Therapeutics has a 12 month low of $0.22 and a 12 month high of $66.33. The stock’s 50 day moving average price is $2.54 and its 200 day moving average price is $168.66.

TransCode Therapeutics Company Profile

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.